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Yellow fever vaccine–associated viscerotropic disease 
is a rare sequela of live-attenuated virus vaccine. Elderly 
persons and persons who have had thymectomies have 
increased susceptibility. A review of published and other 
data suggested a higher than expected number of deaths 
from yellow fever vaccine–associated viscerotropic 
disease among women 19–34 years of age without known 
immunodeﬁ  ciency.
Y
ellow fever virus (YFV) vaccine had been considered 
the safest of the live-virus vaccines. Rare neurologic 
adverse events, called yellow fever vaccine–associated 
neurotropic disease (YEL-AND), have long been 
recognized but are seldom fatal. However, in 2001, the 
vaccine was found to cause a serious, frequently fatal, 
multisystemic illness, called yellow fever vaccine–
associated viscerotropic disease (YEL-AVD), which 
resembles the illness it was designed to prevent (1–3). 
According to reports from the Vaccine Adverse Event 
Reporting System (VAERS) (www.vaers.hhs.gov), the 
frequency of YEL-AVD in US vaccinees was 0.4 per 
100,000 doses of vaccine administered (4).
Elderly persons (4) and patients who have undergone 
thymectomies secondary to thymoma (5) are recognized 
as groups at risk for YEL-AVD. However, several case 
reports of YEL-AVD in young women raise concern that 
women of childbearing age might also be at increased risk 
(6–10).
The Study
To investigate the possibility of age- and sex-speciﬁ  c 
risk groups, a comprehensive YEL-AVD dataset (Table 
36-30 in 11), was analyzed (Figure). This dataset has the 
advantage of having been compiled with information that 
is not otherwise publicly available: data from the Centers 
for Disease Control and Prevention (Atlanta, GA, USA), 
patient charts, and vaccine manufacturers (T.P. Monath, 
pers. comm.).
Two concentrations of cases were evident: cases in 
men >60 years of age who survived and in women 19–34 
years of age who died. Although selection bias may have 
inﬂ  uenced the cases reported, the sex-speciﬁ  c survival rates 
for these 2 age groups statistically differed: 21% (3/14) 
versus 0% (0/6) (p = 0.002 by Fisher exact test). In addition 
to the surprisingly low case-fatality rate for elderly men, 
only 2 of the 4 patients who had undergone thymectomy 
and had YEL-AVD died.
Searches for additional YEL-AVD cases among 
women of childbearing age (15–44 years) and of 
comparably aged men included review of published cases 
through PubMed (www.ncbi.nlm.nih.gov/sites/entrez) and 
reports from the ProMED Web site (http://apex.oracle.
com/pls/otn/f?p=2400:1000:). In follow-up of a ProMED 
listing, 1 case was supplied by Bio-Manguinhos (Rio de 
Janeiro, Brazil), a producer of YFV vaccine. VAERS also 
was searched. Information was sought from authors of case 
reports. Cases listed in VAERS were excluded if another 
explanation for the adverse event was evident in the case 
description or if they contained insufﬁ  cient information to 
classify the event as YEL-AVD.
A total of 9 fatal cases of YEL-AVD in young adults, 
all women, were found (Table). Six cases were included 
in the report by Monath et al. (11), and 3 cases were found 
through the author’s search. The eldest of the 9 case-
patients was 34 years of age. One case listed by Monath 
et al. occurred in 1975 and was originally thought to be 
yellow fever but was documented as vaccine-related ≈2 
decades later (13). This patient’s age is not known, but she 
was reported to be a young woman (P. Vasconcelos, pers. 
comm.).
Three fatal cases of possible YEL-AVD among young 
women reported in VAERS were excluded from the Table 
because information was insufﬁ   cient to document the 
diagnosis. Two other cases of suspected YEL-AVD, 1 each 
in an 18-year-old man and a 24-year-old woman, occurred 
outside the United States. Hence, these patients could have 
come from regions where yellow fever was endemic and 
thus might have had wild-type yellow fever.
Also excluded from the Table are 2 cases reported in 
the published literature: 1 in a 23-year-old woman with 
a partial C4 deﬁ  ciency and discoid lupus erythematosis 
hospitalized with severe YEL-AND and YEL-AVD 
who survived (14) and 1 in a 43-year-old woman with 
systemic lupus erythematosus who died (10). The ﬁ  rst was 
excluded because she survived, had clinical features that 
included YEL-AND, and had known immunodeﬁ  ciency. 
For the second patient, a history of disseminated lupus 
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death (in contrast to the 9–14 days in the other women), and 
her older age suggest that her susceptibility to the vaccine 
differed from those listed in the Table.
In several investigations of YEL-AVD cases, 
extensive sequence analyses did not indicate any 
substantial evidence of reversion of the vaccine to 
virulence (1,10). Two varieties of YFV vaccine are 
available: the 17DD vaccine produced in Brazil and 
used in South America and the 17D-204 vaccine (YF-
Vax, Sanoﬁ   Pasteur, Swiftwater, PA, USA; and Stamaril, 
Sanoﬁ   Pasteur, Lyon, France) used elsewhere. Six cases 
listed in the Table occurred in 17DD vaccine recipients in 
South America, and 3 occurred in persons who received 
17D-204 as prospective travelers.
The limited racial information available indicates that 
cases were not conﬁ  ned to persons of any particular racial 
group. Of 3 case-patients for whom racial information was 
available, 1 each was described as Caucasian (8), black (2), 
and of Paciﬁ  c Islander ancestry (7).
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Table. Characteristics of fatal yellow fever vaccine–associated viscerotropic disease in women of childbearing age who had no known 
immunologic defects* 
Age, y  Country  Year  Vaccine 
Days after 
vaccination 
Possible
predisposing
factors  Virus detection 
Neutralizing
antibody test 
results  Reference  Onset Death
19 Brazil 2001  17DD†  2 10 None known  + RT-PCR liver and 
spleen
(12)
22 United
States
2002 17D-204
YF-Vax‡ 
2 10 None known  YF viral antigen in 
multiple organs, i.e., 
liver, lungs, brain, heart, 
spleen, kidney, lymph 
nodes
(7)
22 United
States
2005 17D-204
YF-Vax‡ 
2 11 See text for 
postmortem
description of 
thymus  
Plasma virus 1.1 × 10
5
PFU/mL 
2,560, day 10  (9)
22 Brazil 2000  17DD†  4 11 Hepatitis A and 
nephritis as a 
child 
+ Culture  IgM +  (2)
23 Peru  2007  17DD†  1 9 Acne rosacea  Viral RNA lung 7.6 × 10
6
and serum 3.9 × 10
6
PFU equivalents/mL 
160 (by PRNT), day 
9
(10)
Young 
adult § 
Brazil 1975  17DD†  5 9 None known  + Culture  Table 36-
30 in (11),
(13)
24 Peru  2007  17DD†  <1 14 Egg allergy  Viral RNA liver 1.1 × 10
4
and brain 4.2 × 10
3 PFU 
equivalents/mL
10,240 (by PRNT), 
day 11 
(10)
26 Spain 2004  17D-204¶  4 10 None known  + Culture liver, kidney, 
plasma; real-time PCR 
liver 6.2 × 10
9 genome 
equivalents/g
512 (by 
microneutralization
assay), day 8 
(8)
34 Brazil 2009  17DD†  1 11 None known  RT-PCR + d 10  #
*+, positive test result; RT-PCR, reverse transcription PCR; YF, yellow fever; Ig, immunoglobulin; PRNT, plaque-reduction neutralization test. Blank cells 
indicate information is not in the reference cited. 
†Bio-Manguinhos, Rio de Janeiro, Brazil. 
‡Sanofi Pasteur, Swiftwater, PA, USA. 
§The age of this patient is not known, but she was a young woman (P. Vasconcelos, pers. comm.). 
¶Stamaril, Sanofi Pasteur, Lyon, France. 
#R. Menezes-Martins, pers. comm. 
Figure. Cases of yellow fever vaccine–associated viscerotropic 
disease, by patient age, sex, and outcome. One woman who 
died and whose precise age is unknown was a young woman (P. 
Vasconcelos, pers. comm.) arbitrarily depicted as being 23 years of 
age. Data obtained from Table 36-30 in (11).Yellow Fever Virus Vaccine and Deaths
Despite the known association of thymectomy with 
YEL-AVD, the only observation on possible thymic 
disease in the reports of the 9 cases is the statement that, at 
autopsy of a 22-year-old woman from the United States, 
the thymus was replaced by fat (Table 36-30 in 11). 
However, the accuracy of the ﬁ  nding should be considered 
in the context that, at surgery, experienced cardiothoracic 
surgeons may have difﬁ  culty in distinguishing thymus 
from adipose tissue (R.L. Berger, pers. comm.) and 
that the thymus was not examined histologically (R.V. 
Ridenour, III, pers. comm.). Because the thymus may 
be difﬁ  cult to separate from surrounding adipose tissue 
and is infrequently a source of disease, pathologists, at 
least in the United States, do not routinely examine it 
histologically at autopsy (I. Argani, pers. comm.). Thymic 
deﬁ  ciencies such as Sutton thymic dysplasia (fatal viral 
infection in young women with a dysplastic thymus) (15) 
have yet to be excluded.
Conclusions
Although accurate denominators are not available 
for calculating age- and sex-speciﬁ  c incidence of YEL-
AVD, the number of fatal YEL-AVD cases among women 
of childbearing age appears to be higher than expected. 
Further investigation should include ascertainment of 
family history; exploration of contraceptive medications 
or occult pregnancy as possible predisposing factors; 
examination of the thymus at postmortem, including 
thymus weight and histology; further evaluation of possible 
complement defects; and evaluation of any associations 
with autoimmune disease.
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